Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China.
State Key Laboratory of Oncology in South China, Department of Pharmacy, Tumor Hospital affiliated to Sun Yat-Sen University, Guangdong, Guangzhou, China. huanghb321@hotmail.com
Hong-Bing
HB
Huang
Ying
Y
Pan
Tao
T
Liu
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002681:China / Q000453:epidemiology; D004363:Drug Utilization / Q000639:trends*; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab